Company profile
Semnur Pharmaceuticals, Inc. CIK 1913577
Tickers
SMNR (OTC) · SMNRW (OTC)
Industry
Pharmaceutical Preparations
Headquarters
Palo Alto, CA 94303
Fiscal year end
2025 (FY)
Key Financials
Revenue
—
Net income
-$160.42M
Total assets
$1.35M
Total liabilities
$22.10M
Stockholders' equity
-$20.75M
Cash & equivalents
$20.0K
Operating income
-$160.42M
Operating cash flow
-$5.87M
Capital expenditures
—
Fiscal year 2025, via 10-K filed 2026-02-27. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
1,641.6%
Equity / assets
-1,541.6%
CapEx / revenue
—
Operating cash flow / net income
0.04×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025
—
-$160.42M
$1.35M
$22.10M
-$20.75M
2024
—
-$4.69M
$6.68M
$49.47M
-$42.78M
2023
—
$632.5K
$50.69M
$8.49M
-$38.09M
2022
—
-$419.4K
$86.28M
$4.18M
-$3.27M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 10-Q
2026-08-10
Financials filed via
Form 10-K
filed 2026-02-27
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
Palo Alto, CA 94303
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:20 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.